Q4 2025 Novavax Inc Earnings Call Transcript

Feb 26, 2026 / 01:30 PM GMT

Release Date Price: $11.19 (+17.42%)

Transcript 8-K10-K

Key Points

Positve

Novavax Inc (NVAX) reported a 65% year-over-year increase in total revenue, reaching $1.1 billion for 2025.
The company successfully signed a new agreement with Pfizer for MatrixM, which could potentially generate billions in revenue through milestones and royalties.
Novavax Inc (NVAX) has significantly decreased its R&D and SG&A expenses by 42% and 53% respectively, demonstrating effective cost management.
The company has secured over $800 million in non-dilutive capital from partnerships with Pfizer and Sanofi over the last 18 months.
Novavax Inc (NVAX) has a strong cash position, ending 2025 with $857 million in cash and accounts receivables, and expects to fund operations into 2028 without new cash flow.

Negative

The macro and regulatory environment in the United States poses significant uncertainties for vaccine companies, which could impact Novavax Inc (NVAX).
Despite progress, the company still faces challenges in converting MTAs into formal partnerships, with timelines largely dependent on partner development schedules.
Novavax Inc (NVAX) is not currently investing in its own flu and COVID combination programs, focusing instead on out-licensing and partnerships.
The company anticipates a front-loaded cost structure in 2026 due to manufacturing support and R&D activities, which may impact short-term financial performance.
There is uncertainty regarding the timing and achievement of certain milestones, such as the $125 million milestone linked to Sanofi's flu-COVID combination phase 3 study.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NVAX.OQ - Novavax Inc
Q4 2025 Novavax Inc Earnings Call
Feb 26, 2026 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Novavax's 4th quarter and full year 2025 financial results and operational highlights conference call.

All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the key followed by 0.

After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then the number one on your touchtone phone. To withdraw your question, please press star, then the number one again. Please note this event is being recorded. I would now like to turn the conference over to Louisunne, Vice President, Investor Relations. Please go ahead.

----------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.